Company Description
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026.
The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
| Country | Belgium |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 558 |
| CEO | Henry Gosebruch |
Contact Details
Address: SchaliEnhoevedreef 20 T Mechelen, 2800 Belgium | |
| Phone | 32 1 534 29 00 |
| Website | lakefrontbio.com |
Stock Details
| Ticker Symbol | LKFT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001421876 |
| CUSIP Number | 36315X101 |
| ISIN Number | US36315X1019 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Henry Gosebruch | Chief Executive Officer and Executive Director |
| Aaron L. Cox | Chief Financial Officer |
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | Head of Investor Relations |
| Fred W. Blakeslee II | Executive Vice President and General Counsel |
| Marieke Vermeersch | Head of Corporate Communication |
| Tania Philipp | Chief Human Resources Officer |
| Ellen Van Der Aar | Head of Development |
| Annelies Missotten | Executive Officer |
| Dr. Jeevan Shetty | Head of Clinical Development Oncology |
| Ruiz Astigarraga | Head of Manufacturing Cell Therapy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2026 | 6-K | Report of foreign issuer |
| Jun 23, 2026 | SCHEDULE 13G | Filing |
| Jun 16, 2026 | 6-K | Report of foreign issuer |
| Jun 9, 2026 | 6-K | Report of foreign issuer |
| Jun 9, 2026 | 6-K | Report of foreign issuer |
| Jun 5, 2026 | 6-K | Report of foreign issuer |
| May 27, 2026 | 6-K | Report of foreign issuer |
| May 8, 2026 | 424B3 | Prospectus |
| May 6, 2026 | 6-K | Report of foreign issuer |
| Apr 29, 2026 | 6-K | Report of foreign issuer |